A phase 1b/2 study of onvansertib in combination with paclitaxel in triple-negative metastatic breast cancer patients.

Protocol # :
Breast Cancer
Invasive Breast Cancer
Unresectable Breast Carcinoma
Locally Advanced Breast Cancer
Metastatic Breast Cancer
Inflammatory Breast Cancer
Triple Negative Breast Cancer (TNBC)
Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Negative Breast Carcinoma
Disease Sites
Principal Investigator
Giordano, Antonio
Site Research Nurses
Abraham, Elizabeth
Beeler, Maureen
Bowers, Jordan
Campbell, Margaret
Cung, Connie
Dishman, Rachel, C.
Ficociello, Samantha
Jeon, Maryangel, H.
Jeon, Maryangel, H.
Kasparian, Elizabeth
Loeser, Wendy
Orechia, Meghan
Padden, Sarah
Patel, Nikita
Roche, Kathleen, A.
Rutter, Morgan
Weitz, MaryAnn

Trial Description

This research is being done to evaluate the safety and effectiveness of Onvansertib in
combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other
parts of the body.

The names of the study interventions involved in this study are:

- Onvansertib

- Paclitaxel

Eligibility Requirements

Inclusion Criteria:

- Histologically confirmed invasive breast cancer with unresectable locally advanced or
metastatic disease, included inflammatory breast cancer

- Histologically or cytologically-confirmed triple negative breast cancer (defined as ER
≤ 10%, PR ≤ 10%, Her-2-neu negative per ASCO/CAP 2018 guidelines: 0-1+ by IHC or

- Concurrent endocrine therapy will not be allowed for patients with ER/PR ≥1%

- Age ≥ 18 years

- ECOG Performance Status of 0 or 1.

- Subjects must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal

- Subject is not receiving any other cancer therapy. Subjects participating in surveys
or observational studies are allowed.

- Subjects with treated brain metastases that are stable on imaging for at least four
weeks prior to registration and who are off steroid therapy are eligible. Subjects
with small, asymptomatic incidental brain metastases that require no immediate
treatment, including steroids, are also eligible.

- For a male or a woman of child-bearing potential (WOCBP): Must agree to use
contraception or take measures to avoid pregnancy during the study and for 180 days of
the final dose of any study drug.

- Adequate contraception is defined as follows:

- Complete true abstinence.

- Consistent and correct use of one of the following methods of birth control:

- Male partner who is sterile prior to the female subjects entry into the study and
is the sole sexual partner for that female patient.

- Intrauterine device (IUD) with a documented failure rate of less than 1% per

- WOCBP must have a negative serum or urine pregnancy test within 5 days prior to

-- WOCBP include any female who has experienced menarche and who has not undergone
successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral
oophorectomy) or is not postmenopausal (defined as amenorrhea > 12 consecutive
months); or women with documented serum follicle stimulating hormone (FSH) in
postmenopausal level according to lab reference level. Even women who are using oral,
implanted or injectable contraceptive hormones or mechanical products such as an IUD
or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or
practicing abstinence or where partner is sterile (e.g., vasectomy), should be
considered to be of child-bearing potential.

- Must have acceptable organ function as detailed below:

- leukocytes ≥3,000/mcL

- absolute neutrophil count ≥1,500/mcL

- platelets ≥100,000/mcL

- hemoglobin ≥ 9.0 g/dL

- total bilirubin ≤1.5 x institutional upper limit of normal (ULN)

- AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN

- creatinine ≤1.5 ULN or creatinine clearance > 50 ml/minute as calculated by the
Cockcroft-Gault equation

- Must have ability to understand and the willingness to sign a written informed consent
form to provide blood sample(s) for specific correlative assays

Exclusion Criteria:

- Anti-cancer chemotherapy or biologic therapy administered within 21 days or 5
half-lives (whichever is shorter) prior to the first dose of study drug.

- Palliative radiation therapy ≤ 2 weeks from enrollment.

- >3 lines of chemotherapy for metastatic disease in the phase 2 portion; no limit on
prior lines in the dose escalation cohort.

- Disease that has relapsed or progressed less than 6 months after most recent exposure
to any taxane-based therapy in neoadjuvant, adjuvant, or metastatic setting.

- Major surgery within 6 weeks prior to treatment initiation.

- Women who are pregnant or breastfeeding.

- Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would
significantly impede the absorption of an oral agent (e.g., intestinal occlusion,
active Crohn's disease, ulcerative colitis, extensive gastric and small intestine

- Unable or unwilling to swallow study drug.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, clinically significant non-healing or healing wounds, symptomatic
congestive heart failure (CHF) Class II or higher according to the New York Heart
Association (NYHA) Functional Classification), unstable angina pectoris, clinically
significant cardiac arrhythmia, significant pulmonary disease (shortness of breath at
rest or mild exertion), uncontrolled infection or psychiatric illness/social
situations that would limit compliance with study requirements.

- Known active infection with COVID-19 or Human Immunodeficiency Virus (HIV), with
measurable viral titer, and/or active infection with hepatitis B or C (subjects who
have had a hepatitis B virus (HBV) immunization are eligible; subjects with HIV and
CD4+ T-cell (CD4+) counts ≥ 350 cells/uL are eligible; subjects on established ART for
at least four weeks and have an HIV viral load less than 400 copies/mL prior to
enrollment are eligible).

- Clinically significant ascites or pleural effusions.

- Known hypersensitivity to paclitaxel.

- Grade 2 or higher peripheral neuropathy.

- Subjects with a history of other malignancies except: adequately treated non-melanoma
skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
curatively treated with no evidence of disease for > 2 years.

- Any active disease condition that would render the protocol treatment dangerous or
impair the ability of the patient to receive study drug.

- QT interval with Fridericia's correction (QTcF) > 480 milliseconds (Vandenberk 2016).
The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate ECGs.
In the case of potentially correctible causes of QT prolongation, (e.g., medications,
hypokalemia), the triplicate ECG may be repeated once during Screening and that result
may be used to determine eligibility.

- Planned concomitant use of medications known to prolong the QT/QTc interval.

- Presence of risk factors for torsade de pointes, including family history of Long QT
Syndrome or uncorrected hypokalemia

- Strong inhibitors/inducers of CYP3A4 are prohibited